IP Library › Granted Patent US 9,955,677
Granted Patent B2
US 9,955,677 · App. 14/744,592 · Granted May 1, 2018

Non-human animals having a humanized programmed cell death 1 gene

Inventors: Elena Burova (Mount Kisco, NY); Alexander O. Mujica (Elmsford, NY); Ka-Man Venus Lai (Tarrytown, NY); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: REGENERON PHARMACEUTICALS, INC.
A01K67/0278A61K49/0008C07K14/4747C07K16/2803C12Q1/6886G01N33/5038A01K2207/15A01K2217/05A01K2217/072A01K2227/105A01K2267/0331C07K14/435C07K2319/00C07K2319/02C07K2319/03C12Q2600/106C12Q2600/158G01N2333/57G01N2333/70503G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,955,677
App. No.
14/744,592
Granted
May 1, 2018
Kind
B2
Abstract

Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Programmed cell death 1 (Pdcd1) gene. The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Pdcd1 gene so that the non-human animals express a PD-1 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).

Claims (16)

1. A mouse whose genome comprises a humanized Programmed cell death 1 (Pdcd1) gene at an endogenous Pdcd1 locus, wherein the humanized Pdcd1 gene is operably linked to a Pdcd1 promoter and expresses a humanized Programmed cell death 1 (PD-1) polypeptide on the surface of activated T cells in said mouse and wherein said humanized PD-1 polypeptide comprises the N-terminal immunoglobulin V domain of a human PD-1 polypeptide and the intracellular domain of an endogenous mouse PD-1 polypeptide.

2. The mouse of claim 1 , wherein the humanized PD-1 polypeptide is translated in a cell of the mouse with a mouse signal peptide.

3. The mouse of claim 1 , wherein the humanized PD-1 polypeptide comprises the transmembrane sequence of the endogenous PD-1 polypeptide.

4. The mouse of claim 1 , wherein the humanized PD-1 polypeptide comprises amino acids 35-145, 27-145, or 26-169 of a human PD-1 polypeptide.

5. The mouse of claim 1 , wherein the humanized Pdcd1 gene comprises endogenous Pdcd1 exons 1, 4 and 5.

6. The mouse of claim 5 , wherein the humanized Pdcd1 gene further comprises an endogenous Pdcd1 exon 3 in whole or in part.

7. The mouse of claim 5 , wherein the humanized Pdcd1 gene comprises exon 2 of a human Pdcd1 gene.

8. The mouse of claim 7 , wherein the humanized Pdcd1 gene further comprises a human Pdcd1 exon 3 in whole or in part.

9. The mouse of claim 1 wherein the Pdcd1 promoter is a rodent Pdcd1 promoter.

10. The mouse of claim 1 , wherein the Pdcd1 promoter is an endogenous mouse Pdcd1 promoter.

11. The mouse of claim 1 , wherein the humanized Pdcd1 gene comprises exon 2 of a human Pdcd1 gene.

12. The mouse of claim 11 , wherein the humanized Pdcd1 gene further comprises a human Pdcd1 exon 3 in whole or in part.

13. The mouse of claim 12 , wherein the humanized Pdcd1 gene comprises the nucleotide sequence as set forth in SEQ ID NO: 23.

14. The mouse of claim 1 , wherein the mouse is homozygous for the humanized Pdcd1 gene.

15. The mouse of claim 1 , wherein the mouse does not detectably express a full-length endogenous mouse PD-1 polypeptide.

16. A humanized PD-1 polypeptide produced by the mouse of claim 15 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2015
From: BUROVA, ELENA; MUJICA, ALEXANDER O.; LAI, KA-MAN VENUS; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 036404/0064 →
Continuity (4)
Provisional Application 62014181 · Jun 19, 2014
Provisional Application 62086518 · Dec 2, 2014
Provisional Application 62138221 · Mar 25, 2015
Related Publication 20150366174A1 · Dec 24, 2015